Earn CME/CE in your profession:

Continuing Education Activity

Endometriosis is a chronic estrogen-dependent chronic condition characterized by the ectopic implantation of functional tissue lining the uterus (endometrial glands and stroma) outside of the uterine cavity. Endometriosis, a word derived from the Greek endo ‘'inside'', metra ''uterus'' and osis ‘' disease,'' remains to some extent vague, with the most common clinical symptoms being pelvic pain and infertility. Most frequently, endometrial tissue is found in ovaries, resulting in the formation of chocolate cysts, but it can also be found in the Fallopian tubes, uterosacral ligaments, the gastrointestinal tract, and less often in the pleura, pericardium, or the central nervous system. This activity illustrates the evaluation and treatment of endometriosis and reviews the role of the healthcare team in managing patients afflicted with endometriosis.


  • Review the risk factors for developing endometriosis and summarize the epidemiology of the disease.

  • Explain the history and physical exam findings associated with endometriosis and describe the available ways to evaluate the disease.

  • Summarize the treatment and management options available for endometriosis.

  • Outline the importance of interprofessional team communication to improve the outcomes of endometriosis.


Endometriosis is a chronic gynecologic disease characterized by the development and presence of histological elements like endometrial glands and stroma in anatomical positions and organs outside of the uterine cavity. The main clinical manifestations of the disease are chronic pelvic pain and impaired fertility. The localization of endometriosis lesions can vary, with the most commonly involved focus of the disease the ovaries followed by the posterior broad ligament, the anterior cul-de-sac, the posterior cul-de-sac, and the uterosacral ligament.[1] Endometriotic nodules also affect the intestinal tract and the urinary system like the ureter, the bladder, and the urethra. Nevertheless, endometriosis is not limited to the pelvis but can damage extra pelvic structures like the pleura, the pericardium, or the central nervous system.[2] The main theories utilized to explain the pathogenesis of endometriosis are Sampson’s theory, the coelomic metaplastic theory, the stem cell theory, the Müllerian remnant theory, and the vascular and lymphatic metastasis theory.


There are several developed theories about the etiology of endometriosis based on the logical sequel relating the severity of symptoms with the stage of the disease, although none of these proposed models can fully explain the range of clinical manifestations of the disease.[3] The most widely plausible theory is Sampson's assumption, stating that the viable cells in the peritoneal fluid with retrograde menstruation can implant, grow, and infiltrate the peritoneal cavity.[3] Retrograde menstruation is a term used to describe the reflux of the blood backward from the Fallopian tubes to the peritoneum during menstruation. It is a phenomenon quite common in a large proportion of women of reproductive age.[3] An alternative to Sampson's theory is the coelomic metaplastic theory suggested by Meyer. This theory relies on the ability of parietal peritoneum epithelium to differentiate into endometrial tissue, probably under the stimuli of cytokines and growth factors of the endometrial stroma.[4] The hypothesis of metaplasia could justify the occurrence of endometriosis in women without a uterus or a lack of endometria, such as female patients with Mayer-Rokitansky-Küster-Hauser syndrome or the rare cases of males who have endometriosis.[5][6]

To explain the occurrence of endometriosis in the cul-de-sac and uterosacral ligaments, the mainly used theory is the Müllerian remnant theory, suggesting that atypical migration or differentiation of these remnants could imitate endometriotic tissue in the poster pelvic floor.[7] Another theory developed to explain endometriosis is the lymphatic and vascular metastasis theory. This theory proposes that endometrial tissue can infiltrate the lymphatics and vasculature and, through them, get transferred to remote foci like the brain or the pleura or retroperitoneal locations.[8] The stem cell theory could also partially explain the pathogenesis and establishment of endometriosis. There has been growing evidence supporting that the endometrial stem cells might be responsible for the development and progression of endometriosis. Endometrial progenitor cells have not only been recognized in menstrual blood but have also been identified as clonogenic cells in the endometrial lesions. The mechanism of generation and establishing endometriosis might be by the retrograde discarding of the endometrial stem cells in the pelvic cavity either with neonatal uterine bleeding or with menstruation after menarche.[9]

Moreover, the ambiguous pathogenesis of endometriosis led the investigators to research the role of oxidative stress, inflammatory elements, and reactive oxygen species (ROS) as long as genetic and epigenetic factors. Oxidative stress is caused by the imbalance between the reactive oxygen species (ROS) and the body's antioxidant ability. ROS have the potential to damage several components of the cell nucleic acids and proteins. If the enzymatic and non-enzymatic cellular antioxidant capacity is decreased, ROS do not get eliminated from the cells and can be the leading cause of endometriosis.[10] Besides, the inability of just one theory to explain the pathogenesis of endometriosis could be ascribed to the complex interaction between the expression of genes involved in endometriosis, inflammatory reactions, and the disrupted hormone response to these stimuli.

Endometriotic lesions present as a chronic local inflammatory disease and involve alterations in cellular immunity and the expression of inflammatory cytokines. According to previous research, patients with endometriosis have elevated serum levels of a wide number of pro-inflammatory cytokines like IL-1, IL-6, and IL-8, resulting in chemotaxis, recruitment, and activation of peritoneal macrophages and proliferation of monocytes. The surgical excision of the endometriotic lesions leads to a decrease in the serum levels of the interleukins, providing evidence that their local production is the reason for the systematic inflammatory reaction. Tumor necrosis factor-alpha (TNF-a) in the peritoneal fluid, produced by the peritoneal macrophages, amplifies the inflammatory response.[11]

The role of steroid hormones in the pathogenesis of endometriosis is also indisputable. Estrogen is the main hormone responsible for the propagation and expansion of the endometrium. The increased action of aromatase, mainly in the deep infiltrating endometriosis, leads to the locally increased activity of estrogen.[10] On the other hand, the inability of progesterone to have an antagonistic action with estrogen in the endometrial tissue is a determining factor for the establishment of endometriosis.[12] The epigenetic changes are also an undeniable factor in the pathogenesis of endometriosis, and this is demonstrated by the fact that not only women of reproductive age suffer from the disease but also adolescents and younger women with a family history.[13] Specific genetic loci have also been identified for the initiation of the disease, making some women more prone to the disease than others. However, the genetic profile is not yet fully understood.[10]


The determination of the epidemiological measurement features sometimes becomes very difficult since a lot of women often remain asymptomatic and go undiagnosed. The exact prevalence cannot be easily defined since the definitive diagnosis of the disease; a laparoscopic examination needs to be conducted. Endometriosis is estimated to affect approximately 10% to 15% of women of reproductive age, whereas this prevalence increases by up to 70% in women with chronic pelvic pain.[14] In the U.S., according to a more recent survey of the National Hospital Discharge Survey, 11.2% of all women between 18 and 45 years old hospitalized for genitourinary causes were diagnosed with endometriosis, and approximately 10.3% of the women who have undergone gynecologic surgeries have endometriosis.[15] Endometriosis is a disease with a high burden in Europe, and the U.S. has been shown that in Europe, the average annual cost for every patient, including health care and loss of productivity, was approximately €10,000, whereas, in the U.S., the health care cost is 63% higher than the average woman.[7]

The diagnosis of endometriosis in the majority of women is often delayed, and thus, women unavoidably suffer from the pain and the long-term effects of this debilitating disease, including infertility. In women with infertility, endometriosis has been found to be up to 50%, whereas, in adolescents, the incidence of endometriosis is reported to be 47% of those who have experienced laparoscopy for pelvic pain.[15][14] Several predisposing factors have been linked with the risk of developing endometriosis. Early age at menarche (age below 11 years old), shorter duration of menstrual periods(less than 27 days), heavy menstrual bleeding (menorrhagia), and nulliparity increase the risk for endometriosis, indicating and ascertaining the hypothesis that endometriosis is closely linked with the hormonal status of a woman(high estrogen levels and low progesterone).[14]

On the contrary, there are protective factors against endometriosis, mainly acting by lowering the inflammatory process or by decreasing the levels of estrogen in the body. Parity, protracted breastfeeding, current oral contraceptive use, tubal ligation, and smoking are related to a decreased risk for endometriosis.[14] Tubal ligation has been assumed to decrease the risk of endometriosis by hampering the menstrual reflux to reach the pelvic cavity.[14] Prolonged breastfeeding seems to suppress the development of endometriosis through postpartum amenorrhea but also with other mechanisms.[16] Contraceptive use and parity hamper the occurrence of ovulation. Whenever ovulation occurs, it is followed by inflammation and release of pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-a), interleukin 1 (IL-1), and interleukin 6 (IL-6). These cytokines enhance cell proliferation and oxidative stress and lead to increased production of leukotrienes and prostaglandins.[17] Additionally, primary amenorrhea, physical activity, and other dietary and lifestyle habits such as increased intake of omega-3 fatty acids and smoking are associated with a decreased risk for endometriosis. The fact that smoking has an inverse association with the risk of endometriosis attracts a lot of attention. Smoking has a catastrophic effect on almost every aspect of health, but this is not the case with endometriosis.


The understanding of the pathophysiology of endometriosis remains incomplete in many aspects, and there is not a coherent suggested theory to explain all different types of endometriosis, integrating the epigenetic, genetic, immunological, and environmental data. From the proposed pathogenic theories, the most plausible is Sampson’s theory, suggesting that with retrograde menstruation, viable cells and menstrual fragments can migrate through the Fallopian tubes, infiltrate into the peritoneal cavity, and then proliferate and cause chronic inflammation.[3] The fact that retrograde menstruation is a phenomenon caused in a large proportion of women of reproductive age, but not all of them suffer from endometriosis, indicates that retrograde menstruation is not enough by itself to cause endometriosis, indicates that there are also other factors contributing to the generation of disease. Other theories, such as the coelomic metaplastic theory, the vascular and lymphatic metastatic theory, are necessary to explain some forms of endometriosis. The role of oxidative stress and ROS, together with genetic, epigenetic, and environmental factors are necessary to be integrated for a more complete picture of the pathogenesis of endometriosis.

History and Physical

The peak of the disease incidence is greater in women between 25 and 29 years old and lowest in women over 44 years old, whereas the prevalence in whites is higher than the African-Americans.[18] The clinical presentation of the disease differs in women and may be unexpected not only in the presentation but also in the duration. Clinicians usually suspect and are more likely to diagnose the disease in females presenting with the typical symptomatology such as dyspareunia, namely painful sexual intercourse, pelvic pain during menstruation (dysmenorrhea), pain in the urination (dysuria), defecation (dyschezia), and/or infertility.[14] The pain is usually characterized as chronic, cyclic, and progressive (exacerbating over time).[19]

Furthermore, some women suffering from endometriosis experience hyperalgesia, a phenomenon when, even with the application of a nonpainful stimulus, an intolerable painful reaction is released. This condition indicates neuropathic pain. In the case of deep infiltrating endometriosis, the neural damage is caused by the invasion of endometrial stromal cells and mediators such as serotonin, histamine, prostaglandins, and nerve growth factor. These agents are released from mast cells, activated macrophages, and leukocytes, not only damaging directly the sensory nerve fibers but also circulating in the peritoneal fluid.[7] Three subtypes of endometriosis often overlap with each other. These are the superficial peritoneal lesions, the ovarian endometrioma, and the deep infiltrating endometriosis.[20] Notably, the degree of clinical manifestations of the patient is not directly associated with the extent of the disease or the size of endometriosis lesions.[21] Patients with bowel endometriosis often present with a wide range of gastrointestinal symptoms like diarrhea, constipation, abdominal pain, or bloating and could mimic other clinical conditions like inflammatory bowel disease or irritable bowel syndrome.[22] Rectovaginal endometriosis is a very severe deep infiltrating form of the disease involving the vagina, the rectum, and the rectovaginal septum. Most often, it can be presented with bowel irritation, dyspareunia, dysmenorrhea, dyschezia, and rectal bleeding coinciding with menstrual bleeding.[23] Finally, a symptom with great concern is infertility, which often leads clinicians to suspect endometriosis, even in asymptomatic patients.

The endometriotic lesions in ovaries are described as ovarian endometriomas or as pseudocysts. The frequency of ovarian endometriomas accounts for approximately 17% to 44% of women with endometriosis, are bilateral in 50% of the cases[24], and are twice more frequent in the left than in the right ovary due to anatomic variables.[25] They differentiate from the common ovarian cysts by the fact that the endometriotic tissue bleeds inside of the endometriotic cyst, is a well-defined extra ovarian hematoma, and is surrounded by a duplicated ovarian parenchyma, lined by endometrial stroma, epithelium, and glands.[7] Chocolate fluid accumulates, covering the wall and filling in the cyst, containing old degenerated blood products, like hemosiderin-filled macrophages and pigmented histiocytes, resulting in a chocolate-like appearance in laparoscopic imaging.[24] Deep infiltrating endometriosis refers to endometriotic lesions that infiltrate the peritoneum more than 5 mm and cause severe symptomatology.[26] Deep endometriosis can involve additionally the bladder, the ureter, and the bowel, more frequently the rectovaginal septum, and less commonly the sigmoid.[26] Superficial peritoneal lesions are, in most cases, an accidental finding. Still, they sporadically can cause a thickening or hemorrhage of the mucosa or even be the reason for a pathological cervicovaginal smear. The histologic diagnosis of endometriosis could be hindered or obscured by a non-typical appearance of the endometrial glands or even the stroma caused by inflammation, edema, or hemorrhage.[27]


The diagnosis of the disease is usually delayed an average of 4 to 11 years from the onset of symptoms. This phenomenon occurs not only in low and middle-income countries but also in wealthy societies with universal healthcare access.[19] This delay is attributed to the non-existence of a pathognomonic test or biomarker to detect the disease but also to the diversity of symptoms that could be considered physiologic responses during menstruation (like pain and discomfort), but also to the wide range of reported symptoms overlap with other gastrointestinal or gynecological causes. To achieve a proper diagnosis of endometriosis, the physician should start by taking a detailed history and performing a gynecological physical examination. Positive family history, pelvic pain, benign ovarian cysts, pelvic surgeries, and infertility issues enhance and alarm physicians to diagnose endometriosis.[19] Physical examination reveals variable findings, depending on the location and size of the endometriotic lesion.[28] Tenderness on vaginal examination, palpable nodules in the posterior fornix, adnexal masses, and immobility of the uterus are diagnostically indicating findings of endometriosis.[29]

Nevertheless, the absence of physical findings cannot exclude the diagnosis of endometriosis. The gold standard diagnostic tool remains laparoscopy, combined with an exploration of the abdominal cavity and a histological biopsy.[30] The lesions can differ in size and color. They can appear as red, white, or clear vesicular. Black "powder-burns" or "gunshot" lesions have been characterized the endometriotic tissue with a brown or black color.[31] The role of histological confirmation is a bit controversial since macroscopically detected endometriotic lesions cannot always be verified histologically, and vice versa, namely in a macroscopically normal peritoneum, can be detected endometriosis tissue.[30] Direct visualization of the endometriotic lesion alone without a histological confirmation lacks enough diagnostic value since, to a great extent, it relies on the surgical skills and capability of the physician. Because diagnostic laparoscopy is an invasive procedure, it entails risks associated with any invasive process and could lead, albeit rare, to severe complications. Hence, there is a need for a diagnostic transition from surgical to non-surgical options, which could also contribute to a decrease in the time between the onset of symptoms and the diagnosis.

Several other low invasive diagnostic methods have been evaluated regarding their diagnostic value, including magnetic resonance imaging (MRI) and transvaginal ultrasound (TVUS). Transvaginal ultrasound is a diagnostic tool with high sensitivity and specificity for ovarian endometriomas and permits a wide exploration of the pelvic cavity. Endometriomas appear as homogenous formations with a classic ground-glass appearance and low-level internal echoes.[24] TVUS could moreover facilitate the diagnosis of deep infiltrating endometriosis located in the rectovaginal septum, uterosacral ligaments, pouch of Douglas, and vaginal wall.[30]

In an effort to assess whether specific serum, tissue, and urine biomarkers could assist diagnostically for endometriosis, CA125 is elevated in patients with endometriosis, but this test could not stand as a single diagnostic test. The reason behind this is that CA125 can be increased in several pathological conditions except for endometriosis and is not able to define the location of endometriotic lesions.[30] A variety of miRNAs have been found to upregulate or downregulate specific genes and play a significant role in the pathogenesis of infertility and endometriosis, but since many results are contradictory, more research is necessary to elucidate the role of these agents further.

Treatment / Management

The treatment of endometriosis is broadly categorized into two main categories: pharmacological and surgical. Currently, there is no a specific drug that could inhibit the progress of the disease rather than hormonal and non-hormonal agents used to alleviate the symptoms and increase the fertility rates.[32] An empirical medical therapy can be instituted for women with endometriosis symptoms (ie, pelvic pain) even without histological confirmation of the disease[31]. It should be highlighted that since endometriosis is a chronic disease, the treatment is mainly used to alleviate symptoms and not ultimately for the cure.[31] Providers should always remember that response to the therapy does not verify the diagnosis of endometriosis.[31] Many physicians treat women who suffer from persistent pain empirically after taking a detailed history, conducting a thorough physical examination, and excluding other pathologies, even though medical treatment does not improve fertility.[33]

The first-line pharmacological therapy proposed for the management of endometriosis consists of non-steroidal anti-inflammatory drugs, progestins, or combined hormonal contraceptives.[31] Combined hormonal contraceptives can be administered either cyclically or continuously, and they exert their effect by inhibiting follicular development, lowering the levels of LH and FSH, and leading to decidualization and atrophy of the human endometrium.[31][33] Oral contraceptives are generally well-tolerated, affordable drugs, but in case of discontinuance have a high possibility of endometriosis-related pain recurrence.[31] Progestins are another option for the medical treatment of endometriosis. Progestins demonstrate their therapeutic action by inhibiting ovulation and creating a hypoestrogenic milieu, and by binding directly to the progesterone receptors in the endometrium, they cause decidualization and atrophy of endometriotic implants. They can also relieve symptoms by decreasing peritoneal inflammation[34]. Weight gain and acne are potential side effects associated with the administration of progestins.[34] Lastly, non-steroidal anti-inflammatory drugs have been evaluated as very effective against endometriosis-related pain and are supported as first-line medical therapy due to their easy accessibility as over-the-counter drugs and the low adverse-effect profile.

A second-line medical empiric treatment is a three-month trial of gonadotropin-releasing hormone (GnRH) analogs for the suppression of endometriosis-related symptoms.[31] The continuous administration of the GnRH acts by binding to pituitary receptors and downregulating the pituitary-ovarian axis. This results in pituitary desensitization, a fall in the levels of LH and FSH, anovulation, hypoestrogenism, and endometrial atrophy. The only concerns regarding this therapy are related to the side effects of hypogonadism, including bone loss, hot flashes, vaginal dryness, and headache.[35] Danazol, an androgen used to alleviate endometriosis-related symptoms, leads to atrophy of endometriotic implants by hindering LH surge and lowering estrogen levels. On the other hand, testosterone levels increase, and side effects like hirsutism, irreversible deepening of the voice, or acne can appear.[31]Surgical treatment could also be adopted as a potential management option, even though it entails several risks related to the complications.[36] The major advantage of surgical treatment compared to pharmaceutical options is the ability to enhance fertility capability, but it can also provide pain relief simultaneously [7]. Surgery should be considered in cases of superficial endometriosis unresponsive or with contradictions to medical treatment.[7] When laparoscopic surgery is performed, the recommendation is to excise all the endometriotic lesions and adhesions. By the ablation of the endometriotic tissue, the local inflammatory milieu decreases in the pelvic cavity, thus increasing the chances for conception.[36][7] On the other hand, the management of ovarian endometriomas is still challenging and poses a dilemma to clinicians. The reason behind this is the cumulative research evidence that shows that the removal of the capsule of the cyst can result in a decrease in ovarian reserve and follicular loss.[36] However, cystectomy is preferable to cyst drainage or ablation due to its greater effectiveness in pain relief and the lower recurrence rate.[36] The final decision about which treatment approach should be followed should be taken collaboratively with the patient after a detailed explanation of all the possible risks and benefits related to each treatment option.[7]

Differential Diagnosis

The most common symptoms of endometriosis are infertility and chronic cyclic pelvic pain; therefore, other conditions should be ruled out from the differential diagnosis. Chronic pelvic pain is a usual symptom derived from pathologic conditions of the urologic, reproductive, and gastrointestinal systems. Pelvic inflammatory disease, adhesions, endometritis, primary dysmenorrhea, and second dysmenorrhea due to adenomyosis, myoma, and cervical stenosis should be excluded from the pathologies of the genital system.[33] Other diseases that should be excluded come from the gastrointestinal system, like irritable bowel syndrome, constipation, inflammatory bowel disease, and the urinary system, such as interstitial cystitis or chronic urinary inflammation.[37] Finally, the physician should also rule out neurologic and psychosomatic causes leading to chronic pelvic pain.[37]


Patients with endometriosis have fewer chances for childbearing and a higher risk for miscarriages and ectopic pregnancies than those without the disease.[38] Additionally, endometriotic lesions can spontaneously regress in approximately one-third of affected women who are not receiving any treatment.[39] According to different estimates, recurrence rates of endometriosis after surgery vary between 6 and 67%.[40] Potential risk factors predicting a possible recurrence have not been completely clarified, but the recurrent endometriotic lesions may arise from de novo cells or residual endometriotic tissue.[40] Medical treatment can be proven effective, but in 5% to 59% of patients, the pain continues to exist at the end of the therapy.[41] Even in cases of treatment cessation, pain recurrence has been reported in a percentage of 17% to 34%.[41]


The main complications of endometriosis include infertility or subfertility, chronic pain, and other debilitating persistent symptoms. These are entailed in a wide range, including dysmenorrhea, dyspareunia, and dyschezia, but endometriosis can also cause a decrease in the quality of life of patients, complications of surgical procedures, anatomical abnormalities due to possible adhesions, bowel or/and bladder dysfunction, but in the case of ovarian endometriomas could even lead to the development of cancer. The role of endometriosis in infertile women has been debated for a long time, with literature research showing that infertile women are 6 up to 8-fold more likely to suffer from endometriosis than fertile females.[42] Even though several mechanisms have been proposed to explain this phenomenon, no consensus has been reached in the scientific community about the exact mechanism behind infertility in endometriosis.[42]

Chronic pelvic pain is closely associated with endometriosis since endometriosis has been the cause in 71% to 87% of women suffering from chronic pelvic pain.[43] This disease can negatively affect the health-related quality of life and crucially hinder social, emotional, and sexual well-being as well as other domains like daily routines, family planning, efficacy, or productivity of patients in the working environment.[44] Additionally, patients with endometriosis have higher stress levels, report worse quality of sleep, and lower physical activity compared to healthy women.[44] Bowel dysfunction like constipation or other digestive problems can appear in females who have endometriosis as a result of the inflammatory process of irritation of the gastrointestinal system rather than due to the involvement of endometriotic nodules affecting the rectum since patients undergoing surgical treatment for rectal endometriosis might continue experiencing those displeasing symptoms.[45] Although primarily endometriosis was considered a benign condition, later research findings showed a higher risk for ovarian cancer in patients with endometriosis.[46]

Deterrence and Patient Education

Recurrence is common in patients who discontinue therapy or even after the surgery.[31] Patients should be encouraged to continue with medical therapy for several months, even though they might present some adverse effects. Females who undergo surgical treatment should adhere to the doctor’s post-surgical instructions to avoid and minimize postoperative complications such as infections. In case of a recurrence, patients should be encouraged to visit the health care specialist for further evaluation. Nevertheless, women with a diagnosis of the disease should be aware of possible complications of the disease, predominantly the risk for infertility and chronic pelvic pain.

Enhancing Healthcare Team Outcomes

Endometriosis remains a disease with high comorbidity, even though extensive research has been conducted and new medical treatments have been developed. Healthcare professionals need to join hands and work collectively when they need to work with patients with suspected cases of endometriosis. It is not random that the mean delay of a definitive diagnosis of endometriosis is approximately ten years. Public health interventions should be introduced and promote awareness among females of childbearing age for signs and symptoms of endometriosis; thus, they could seek medical care in an earlier stage of the disease.

Clinicians should work as a team regarding the management of endometriosis to achieve the most effective treatment and avoid surgical complications. Additionally, healthcare professionals engaged with the management of endometriosis should be informed about new drugs, their indications or adverse effects to implement a successful treatment, and their attention should be drawn to the fact that the symptomatology of the disease has no direct relationship with the extent of disease.[47] The treatment plan should be personalized and patient-centered, chosen basically by the individual characteristics of each patient. The symptoms, age, and childbearing desire are essential factors that should be communicated with the patient and within the health care team. Endometriosis is a chronic condition. Therefore, the main goals of the healthcare team should be the alleviation of symptoms, the minimization of pain recurrence, and the safety of the patient.



Heba Mahdy


1/23/2023 7:53:15 PM



Jenkins S, Olive DL, Haney AF. Endometriosis: pathogenetic implications of the anatomic distribution. Obstetrics and gynecology. 1986 Mar:67(3):335-8     [PubMed PMID: 3945444]


Macer ML, Taylor HS. Endometriosis and infertility: a review of the pathogenesis and treatment of endometriosis-associated infertility. Obstetrics and gynecology clinics of North America. 2012 Dec:39(4):535-49. doi: 10.1016/j.ogc.2012.10.002. Epub     [PubMed PMID: 23182559]


Koninckx PR, Barlow D, Kennedy S. Implantation versus infiltration: the Sampson versus the endometriotic disease theory. Gynecologic and obstetric investigation. 1999:47 Suppl 1():3-9; discussion 9-10     [PubMed PMID: 10087422]


Matsuura K,Ohtake H,Katabuchi H,Okamura H, Coelomic metaplasia theory of endometriosis: evidence from in vivo studies and an in vitro experimental model. Gynecologic and obstetric investigation. 1999;     [PubMed PMID: 10087424]


Konrad L, Dietze R, Kudipudi PK, Horné F, Meinhold-Heerlein I. Endometriosis in MRKH cases as a proof for the coelomic metaplasia hypothesis? Reproduction (Cambridge, England). 2019 Aug:158(2):R41-R47. doi: 10.1530/REP-19-0106. Epub     [PubMed PMID: 30978694]

Level 3 (low-level) evidence


Jabr FI, Mani V. An unusual cause of abdominal pain in a male patient: Endometriosis. Avicenna journal of medicine. 2014 Oct:4(4):99-101. doi: 10.4103/2231-0770.140660. Epub     [PubMed PMID: 25298953]


Vercellini P, Viganò P, Somigliana E, Fedele L. Endometriosis: pathogenesis and treatment. Nature reviews. Endocrinology. 2014 May:10(5):261-75. doi: 10.1038/nrendo.2013.255. Epub 2013 Dec 24     [PubMed PMID: 24366116]


Jerman LF,Hey-Cunningham AJ, The role of the lymphatic system in endometriosis: a comprehensive review of the literature. Biology of reproduction. 2015 Mar;     [PubMed PMID: 25588508]


Cousins FL, O DF, Gargett CE. Endometrial stem/progenitor cells and their role in the pathogenesis of endometriosis. Best practice & research. Clinical obstetrics & gynaecology. 2018 Jul:50():27-38. doi: 10.1016/j.bpobgyn.2018.01.011. Epub 2018 Feb 8     [PubMed PMID: 29503126]


Asghari S, Valizadeh A, Aghebati-Maleki L, Nouri M, Yousefi M. Endometriosis: Perspective, lights, and shadows of etiology. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2018 Oct:106():163-174. doi: 10.1016/j.biopha.2018.06.109. Epub 2018 Jun 27     [PubMed PMID: 29958140]

Level 3 (low-level) evidence


Tao Y, Zhang Q, Huang W, Zhu H, Zhang D, Luo W. The peritoneal leptin, MCP-1 and TNF-α in the pathogenesis of endometriosis-associated infertility. American journal of reproductive immunology (New York, N.Y. : 1989). 2011 Apr:65(4):403-6. doi: 10.1111/j.1600-0897.2010.00920.x. Epub 2010 Sep 6     [PubMed PMID: 20825374]


DeMayo FJ,Zhao B,Takamoto N,Tsai SY, Mechanisms of action of estrogen and progesterone. Annals of the New York Academy of Sciences. 2002 Mar;     [PubMed PMID: 11949965]


Marsh EE, Laufer MR. Endometriosis in premenarcheal girls who do not have an associated obstructive anomaly. Fertility and sterility. 2005 Mar:83(3):758-60     [PubMed PMID: 15749511]


Parasar P, Ozcan P, Terry KL. Endometriosis: Epidemiology, Diagnosis and Clinical Management. Current obstetrics and gynecology reports. 2017 Mar:6(1):34-41. doi: 10.1007/s13669-017-0187-1. Epub 2017 Jan 27     [PubMed PMID: 29276652]


Eskenazi B, Warner ML. Epidemiology of endometriosis. Obstetrics and gynecology clinics of North America. 1997 Jun:24(2):235-58     [PubMed PMID: 9163765]


Farland LV,Eliassen AH,Tamimi RM,Spiegelman D,Michels KB,Missmer SA, History of breast feeding and risk of incident endometriosis: prospective cohort study. BMJ (Clinical research ed.). 2017 Aug 29;     [PubMed PMID: 28851765]


Ness RB. Endometriosis and ovarian cancer: thoughts on shared pathophysiology. American journal of obstetrics and gynecology. 2003 Jul:189(1):280-94     [PubMed PMID: 12861175]


Missmer SA, Hankinson SE, Spiegelman D, Barbieri RL, Marshall LM, Hunter DJ. Incidence of laparoscopically confirmed endometriosis by demographic, anthropometric, and lifestyle factors. American journal of epidemiology. 2004 Oct 15:160(8):784-96     [PubMed PMID: 15466501]


Agarwal SK, Chapron C, Giudice LC, Laufer MR, Leyland N, Missmer SA, Singh SS, Taylor HS. Clinical diagnosis of endometriosis: a call to action. American journal of obstetrics and gynecology. 2019 Apr:220(4):354.e1-354.e12. doi: 10.1016/j.ajog.2018.12.039. Epub 2019 Jan 6     [PubMed PMID: 30625295]


Borghese B,Santulli P,Marcellin L,Chapron C, [Definition, description, clinicopathological features, pathogenesis and natural history of endometriosis: CNGOF-HAS Endometriosis Guidelines]. Gynecologie, obstetrique, fertilite     [PubMed PMID: 29540335]


Chapron C, Bourret A, Chopin N, Dousset B, Leconte M, Amsellem-Ouazana D, de Ziegler D, Borghese B. Surgery for bladder endometriosis: long-term results and concomitant management of associated posterior deep lesions. Human reproduction (Oxford, England). 2010 Apr:25(4):884-9. doi: 10.1093/humrep/deq017. Epub 2010 Feb 3     [PubMed PMID: 20129993]


Remorgida V, Ferrero S, Fulcheri E, Ragni N, Martin DC. Bowel endometriosis: presentation, diagnosis, and treatment. Obstetrical & gynecological survey. 2007 Jul:62(7):461-70     [PubMed PMID: 17572918]


Moawad NS, Caplin A. Diagnosis, management, and long-term outcomes of rectovaginal endometriosis. International journal of women's health. 2013 Nov 8:5():753-63. doi: 10.2147/IJWH.S37846. Epub 2013 Nov 8     [PubMed PMID: 24232977]


Bastos BB,Fonseca EKUN,Yamauchi FI,Baroni RH, Chocolate cyst with ground glass appearance in endometriomas. Abdominal radiology (New York). 2017 Dec;     [PubMed PMID: 28676998]


Gałczyński K, Jóźwik M, Lewkowicz D, Semczuk-Sikora A, Semczuk A. Ovarian endometrioma - a possible finding in adolescent girls and young women: a mini-review. Journal of ovarian research. 2019 Nov 7:12(1):104. doi: 10.1186/s13048-019-0582-5. Epub 2019 Nov 7     [PubMed PMID: 31699129]


De Cicco C, Corona R, Schonman R, Mailova K, Ussia A, Koninckx P. Bowel resection for deep endometriosis: a systematic review. BJOG : an international journal of obstetrics and gynaecology. 2011 Feb:118(3):285-91. doi: 10.1111/j.1471-0528.2010.02744.x. Epub 2010 Oct 13     [PubMed PMID: 21040395]

Level 1 (high-level) evidence


Clement PB. The pathology of endometriosis: a survey of the many faces of a common disease emphasizing diagnostic pitfalls and unusual and newly appreciated aspects. Advances in anatomic pathology. 2007 Jul:14(4):241-60     [PubMed PMID: 17592255]

Level 3 (low-level) evidence


Vercellini P,Trespidi L,De Giorgi O,Cortesi I,Parazzini F,Crosignani PG, Endometriosis and pelvic pain: relation to disease stage and localization. Fertility and sterility. 1996 Feb;     [PubMed PMID: 8566252]


Hickey M, Ballard K, Farquhar C. Endometriosis. BMJ (Clinical research ed.). 2014 Mar 19:348():g1752. doi: 10.1136/bmj.g1752. Epub 2014 Mar 19     [PubMed PMID: 24647161]


Kiesel L, Sourouni M. Diagnosis of endometriosis in the 21st century. Climacteric : the journal of the International Menopause Society. 2019 Jun:22(3):296-302. doi: 10.1080/13697137.2019.1578743. Epub 2019 Mar 25     [PubMed PMID: 30905186]


Kim JH, Han E. Endometriosis and Female Pelvic Pain. Seminars in reproductive medicine. 2018 Mar:36(2):143-151. doi: 10.1055/s-0038-1676103. Epub 2018 Dec 19     [PubMed PMID: 30566980]


Platteeuw L,D'Hooghe T, Novel agents for the medical treatment of endometriosis. Current opinion in obstetrics     [PubMed PMID: 24978852]

Level 3 (low-level) evidence


Wellbery C. Diagnosis and treatment of endometriosis. American family physician. 1999 Oct 15:60(6):1753-62, 1767-8     [PubMed PMID: 10537390]


Jeng CJ, Chuang L, Shen J. A comparison of progestogens or oral contraceptives and gonadotropin-releasing hormone agonists for the treatment of endometriosis: a systematic review. Expert opinion on pharmacotherapy. 2014 Apr:15(6):767-73. doi: 10.1517/14656566.2014.888414. Epub 2014 Mar 4     [PubMed PMID: 24588662]

Level 3 (low-level) evidence


Magon N. Gonadotropin releasing hormone agonists: Expanding vistas. Indian journal of endocrinology and metabolism. 2011 Oct:15(4):261-7. doi: 10.4103/2230-8210.85575. Epub     [PubMed PMID: 22028996]


Kho RM,Andres MP,Borrelli GM,Neto JS,Zanluchi A,Abrão MS, Surgical treatment of different types of endometriosis: Comparison of major society guidelines and preferred clinical algorithms. Best practice     [PubMed PMID: 29545114]


Wozniak S. Chronic pelvic pain. Annals of agricultural and environmental medicine : AAEM. 2016 Jun 2:23(2):223-6. doi: 10.5604/12321966.1203880. Epub     [PubMed PMID: 27294622]


Hjordt Hansen MV, Dalsgaard T, Hartwell D, Skovlund CW, Lidegaard O. Reproductive prognosis in endometriosis. A national cohort study. Acta obstetricia et gynecologica Scandinavica. 2014 May:93(5):483-9. doi: 10.1111/aogs.12373. Epub     [PubMed PMID: 24617701]


Harrison RF, Barry-Kinsella C. Efficacy of medroxyprogesterone treatment in infertile women with endometriosis: a prospective, randomized, placebo-controlled study. Fertility and sterility. 2000 Jul:74(1):24-30     [PubMed PMID: 10899492]

Level 1 (high-level) evidence


Selçuk I,Bozdağ G, Recurrence of endometriosis; risk factors, mechanisms and biomarkers; review of the literature. Journal of the Turkish German Gynecological Association. 2013;     [PubMed PMID: 24592083]

Level 2 (mid-level) evidence


Becker CM, Gattrell WT, Gude K, Singh SS. Reevaluating response and failure of medical treatment of endometriosis: a systematic review. Fertility and sterility. 2017 Jul:108(1):125-136. doi: 10.1016/j.fertnstert.2017.05.004. Epub     [PubMed PMID: 28668150]

Level 1 (high-level) evidence


Bulletti C, Coccia ME, Battistoni S, Borini A. Endometriosis and infertility. Journal of assisted reproduction and genetics. 2010 Aug:27(8):441-7. doi: 10.1007/s10815-010-9436-1. Epub 2010 Jun 25     [PubMed PMID: 20574791]


Bloski T, Pierson R. Endometriosis and Chronic Pelvic Pain: Unraveling the Mystery Behind this Complex Condition. Nursing for women's health. 2008 Oct:12(5):382-95. doi: 10.1111/j.1751-486X.2008.00362.x. Epub     [PubMed PMID: 18837717]


Marinho MCP,Magalhaes TF,Fernandes LFC,Augusto KL,Brilhante AVM,Bezerra LRPS, Quality of Life in Women with Endometriosis: An Integrative Review. Journal of women's health (2002). 2018 Mar;     [PubMed PMID: 29064316]

Level 2 (mid-level) evidence


Roman H, Bridoux V, Tuech JJ, Marpeau L, da Costa C, Savoye G, Puscasiu L. Bowel dysfunction before and after surgery for endometriosis. American journal of obstetrics and gynecology. 2013 Dec:209(6):524-30. doi: 10.1016/j.ajog.2013.04.015. Epub 2013 Apr 10     [PubMed PMID: 23583209]


Králíčková M, Laganà AS, Ghezzi F, Vetvicka V. Endometriosis and risk of ovarian cancer: what do we know? Archives of gynecology and obstetrics. 2020 Jan:301(1):1-10. doi: 10.1007/s00404-019-05358-8. Epub 2019 Nov 19     [PubMed PMID: 31745637]


Mehedintu C, Plotogea MN, Ionescu S, Antonovici M. Endometriosis still a challenge. Journal of medicine and life. 2014 Sep 15:7(3):349-57     [PubMed PMID: 25408753]